Targets (70)
| Target | Programs | Companies | Trials |
|---|
| GPRC5D | 62 | 61 | 104 |
| C5 | 60 | 58 | 101 |
| B7-H3 | 58 | 54 | 88 |
| AuroraA | 57 | 57 | 92 |
| WRN | 54 | 54 | 86 |
| GLP-1R | 53 | 50 | 87 |
| FXIa | 53 | 51 | 77 |
| KRASG12C | 52 | 50 | 91 |
| JAK2 | 52 | 51 | 91 |
| CD38 | 52 | 49 | 99 |
| FcRn | 51 | 51 | 89 |
| CFTR | 51 | 49 | 91 |
| IL-17A | 50 | 47 | 82 |
| PLK4 | 50 | 50 | 80 |
| CDK4/6 | 49 | 48 | 83 |
| PARP | 49 | 49 | 78 |
| MALT1 | 49 | 48 | 80 |
| PRMT5 | 47 | 46 | 85 |
| RET | 46 | 45 | 74 |
| CGRP | 46 | 44 | 75 |
| SHP2 | 46 | 45 | 83 |
| MDM2 | 46 | 45 | 70 |
| PI3Kα | 45 | 42 | 69 |
| GIP-R | 45 | 43 | 82 |
| Tau | 45 | 43 | 74 |
| CDK2 | 45 | 43 | 77 |
| PD-L1 | 44 | 43 | 84 |
| TROP-2 | 44 | 43 | 66 |
| TYK2 | 44 | 44 | 80 |
| BET | 44 | 44 | 76 |
| MET | 43 | 40 | 77 |
| CD20 | 43 | 41 | 68 |
| VEGF | 42 | 40 | 71 |
| HER2 | 42 | 42 | 71 |
| TIM-3 | 42 | 42 | 66 |
| IL-23 | 42 | 42 | 76 |
| Aβ | 42 | 41 | 82 |
| KRASG12D | 42 | 42 | 68 |
| DLL3 | 42 | 41 | 73 |
| SOS1 | 42 | 39 | 71 |
| CD19 | 41 | 41 | 65 |
| TNFα | 41 | 40 | 63 |
| PCSK9 | 41 | 38 | 67 |
| BCMA | 41 | 39 | 71 |
| EZH2 | 41 | 41 | 73 |
| KIF18A | 41 | 41 | 85 |
| IL-13 | 40 | 38 | 75 |
| PD-1 | 39 | 39 | 71 |
| SGLT2 | 39 | 38 | 70 |
| FGFR | 39 | 38 | 74 |
| FLT3 | 39 | 39 | 72 |
| SMN2 | 39 | 39 | 67 |
| Menin | 39 | 38 | 66 |
| PSMA | 39 | 38 | 65 |
| Nectin-4 | 39 | 38 | 65 |
| CD47 | 39 | 39 | 64 |
| USP1 | 39 | 38 | 64 |
| BCL-2 | 38 | 38 | 58 |
| TIGIT | 38 | 38 | 64 |
| LAG-3 | 37 | 34 | 61 |
| WEE1 | 37 | 37 | 64 |
| CD3 | 36 | 35 | 56 |
| APOC3 | 36 | 36 | 54 |
| AHR | 36 | 36 | 52 |
| JAK1 | 35 | 35 | 56 |
| Cl18.2 | 35 | 34 | 59 |
| EGFR | 33 | 33 | 62 |
| CD123 | 31 | 31 | 56 |
| BTK | 30 | 28 | 52 |
| ALK | 25 | 23 | 35 |